Abstract
Recently, disease-related proteinshave received attention for advanced drug therapies. Indeed, attempts are being made to develop a wide variety of therapeutic proteins for diseases including cancerand autoimmune conditions.Unfortunately, however, the utilization of bioactive proteins in clinical practice is often limited because of their inherent instability and pleiotropic actions in vivo. Our project aims to overcome two major problems, details of which will be addressed in separate sections to follow. (i) Development of a system rapidly creating functional mutant proteinswith enhanced affinityor specificitytothe receptors using a phage display technique. (ii) Establishment of apolymer-conjugation system improving in vivo stability and selectively of bioactive proteins (polymeric DDS). In this review, we introduce our DDS-based technologies for next-generation biodrug development.
